文献速递特殊人群用药治疗药物监测与药物基因组学

利福平在成人与儿童群体中的群体药代动力学分析:系统综述

Population pharmacokinetics analyses of rifampicin in adult and children populations: A systematic review.
PubMed 文献 · Br J Clin Pharmacol · 2022-03-30

AIMS: Rifampicin has become an essential component as the first-line therapy for pulmonary tuberculosis (PTB). Several population pharmacokinetic (PK) studies on rifampicin in adult and child populations have been studied previously, therefore the aims of the systematic review we…

要点

  • 利福平群体PK模型多采用单室带瞬态吸收室和一阶消除。
  • 制剂、体重、性别、妊娠、糖尿病和营养补充为显著协变量。
  • 仅2项研究进行外部验证,模型预测性能需更多验证。

核心结论

  • 利福平PK参数的变异来源仍不一致且了解不足,需探索其他因素并严格采样策略以获取可靠信息。
  • 应频繁进行外部验证以提高模型预测性能。

主要发现

  • 大多数研究中利福平结构模型为单室带瞬态吸收室和一阶消除。
  • 制剂、体重、性别、妊娠状态、糖尿病和营养补充是影响PK参数的显著协变量。
  • 仅2项研究对开发的PK模型进行了外部验证。

临床怎么用

  • 临床药学智能体可参考已识别的显著协变量(制剂、体重、性别、妊娠、糖尿病、营养补充)评估利福平个体化给药。
  • 应用群体PK模型时需注意多数模型缺乏外部验证,应谨慎解读预测结果。

局限性

  • 利福平PK参数变异来源不一致且了解不足。
  • 外部验证仅2项,模型预测性能证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Rifampicin has become an essential component as the first-line therapy for pulmonary tuberculosis (PTB). Several population pharmacokinetic (PK) studies on rifampicin in adult and child populations have been studied previously, therefore the aims of the systematic review were (i) to summarize the relevant published studies and significant covariates that influence the PK of rifampicin across different populations, and (ii) to identify any knowledge gap that requires additional research in the future. METHODS: A total of 121 relevant population PK articles were systematically identified using PubMed and Scopus from inception to October 2021. Review articles, in-vitro and physiological methods, animal studies and noncompartmental analysis were excluded. RESULTS: Nineteen studies, of which 16 involved adults, two involved children, and one involved both adults and children, were included in the review. The structural model of rifampicin can be described as one compartment with a transient compartment absorption model and first-order elimination in most of the studies. Pharmaceutical formulation, body weight, gender, pregnancy status, diabetes and nutritional supplementation were found to be the significant covariates that affect the PK parameters. External validation of the developed PK model was only conducted in two studies. CONCLUSIONS: The source of variability for PK parameters of rifampicin remains inconsistent and poorly understood even though there were many potential covariates investigated in the selected studies. Exploring other possible factors and implementing a strict sampling strategy by considering the induction effects might uncover precise and reliable information. Furthermore, external validation should be frequently conducted to produce better predictability of model performance.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Muda MR, Harun SN, Syed Sulaiman SA, et al. Population pharmacokinetics analyses of rifampicin in adult and children populations: A systematic review. Br J Clin Pharmacol. 2022. PMID: 35253251. doi:10.1111/bcp.15298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。